1191 related articles for article (PubMed ID: 32032529)
1. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease.
Richardson P; Griffin I; Tucker C; Smith D; Oechsle O; Phelan A; Rawling M; Savory E; Stebbing J
Lancet; 2020 Feb; 395(10223):e30-e31. PubMed ID: 32032529
[No Abstract] [Full Text] [Related]
2. Janus kinase inhibitor baricitinib is not an ideal option for management of COVID-19.
Praveen D; Puvvada RC; M VA
Int J Antimicrob Agents; 2020 May; 55(5):105967. PubMed ID: 32259575
[TBL] [Abstract][Full Text] [Related]
3. Baricitinib as rescue therapy in a patient with COVID-19 with no complete response to sarilumab.
Cingolani A; Tummolo AM; Montemurro G; Gremese E; Larosa L; Cipriani MC; Pasciuto G; Liperoti R; Murri R; Pirronti T; Cauda R; Fantoni M;
Infection; 2020 Oct; 48(5):767-771. PubMed ID: 32642806
[TBL] [Abstract][Full Text] [Related]
4. Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19.
Zhang X; Zhang Y; Qiao W; Zhang J; Qi Z
Int Immunopharmacol; 2020 Sep; 86():106749. PubMed ID: 32645632
[TBL] [Abstract][Full Text] [Related]
5. COVID-19: an unexpected indication for anti-rheumatic therapies?
Lucchino B; Di Franco M; Conti F
Rheumatology (Oxford); 2020 Jun; 59(6):1200-1203. PubMed ID: 32374874
[No Abstract] [Full Text] [Related]
6. HiJAKing SARS-CoV-2? The potential role of JAK inhibitors in the management of COVID-19.
Spinelli FR; Conti F; Gadina M
Sci Immunol; 2020 May; 5(47):. PubMed ID: 32385052
[TBL] [Abstract][Full Text] [Related]
7. Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients.
Stebbing J; Krishnan V; de Bono S; Ottaviani S; Casalini G; Richardson PJ; Monteil V; Lauschke VM; Mirazimi A; Youhanna S; Tan YJ; Baldanti F; Sarasini A; Terres JAR; Nickoloff BJ; Higgs RE; Rocha G; Byers NL; Schlichting DE; Nirula A; Cardoso A; Corbellino M;
EMBO Mol Med; 2020 Aug; 12(8):e12697. PubMed ID: 32473600
[TBL] [Abstract][Full Text] [Related]
8. Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy.
Ceribelli A; Motta F; De Santis M; Ansari AA; Ridgway WM; Gershwin ME; Selmi C
J Autoimmun; 2020 May; 109():102442. PubMed ID: 32253068
[TBL] [Abstract][Full Text] [Related]
9. What is the role of rheumatologists in the era of COVID-19?
Marotto D; Sarzi-Puttini P
Autoimmun Rev; 2020 Jun; 19(6):102539. PubMed ID: 32251716
[No Abstract] [Full Text] [Related]
10. [Baricitinib in the treatment of SARS-CoV-2 infection].
Gutiérrez-Lorenzo M; Cuadros-MartÃnez CM
Rev Esp Quimioter; 2020 Aug; 33(4):294-295. PubMed ID: 32583654
[No Abstract] [Full Text] [Related]
11. COVID-19: Review on latest available drugs and therapies against SARS-CoV-2. Coagulation and inflammation cross-talking.
Magro G
Virus Res; 2020 Sep; 286():198070. PubMed ID: 32569708
[TBL] [Abstract][Full Text] [Related]
12. The type I interferon response in COVID-19: implications for treatment.
Lee JS; Shin EC
Nat Rev Immunol; 2020 Oct; 20(10):585-586. PubMed ID: 32788708
[TBL] [Abstract][Full Text] [Related]
13. Baricitinib: A Review of Pharmacology, Safety, and Emerging Clinical Experience in COVID-19.
Jorgensen SCJ; Tse CLY; Burry L; Dresser LD
Pharmacotherapy; 2020 Aug; 40(8):843-856. PubMed ID: 32542785
[TBL] [Abstract][Full Text] [Related]
14. Pronounced benefits of JAK inhibition with baricitinib in COVID-19 pneumonia in obese but not lean subjects.
David P; Hen O; Ben-Shabbat N; Macleod T; Amital H; Watad A; McGonagle DG
RMD Open; 2024 May; 10(2):. PubMed ID: 38796180
[TBL] [Abstract][Full Text] [Related]
15. COVID-19: combining antiviral and anti-inflammatory treatments.
Stebbing J; Phelan A; Griffin I; Tucker C; Oechsle O; Smith D; Richardson P
Lancet Infect Dis; 2020 Apr; 20(4):400-402. PubMed ID: 32113509
[No Abstract] [Full Text] [Related]
16. Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact.
Cantini F; Niccoli L; Matarrese D; Nicastri E; Stobbione P; Goletti D
J Infect; 2020 Aug; 81(2):318-356. PubMed ID: 32333918
[TBL] [Abstract][Full Text] [Related]
17. CNS penetration of potential anti-COVID-19 drugs.
Richardson PJ; Ottaviani S; Prelle A; Stebbing J; Casalini G; Corbellino M
J Neurol; 2020 Jul; 267(7):1880-1882. PubMed ID: 32361836
[No Abstract] [Full Text] [Related]
18. JAK Inhibition as a New Treatment Strategy for Patients with COVID-19.
Seif F; Aazami H; Khoshmirsafa M; Kamali M; Mohsenzadegan M; Pornour M; Mansouri D
Int Arch Allergy Immunol; 2020; 181(6):467-475. PubMed ID: 32392562
[TBL] [Abstract][Full Text] [Related]
19. Thoughts on COVID-19 and autoimmune diseases.
Askanase AD; Khalili L; Buyon JP
Lupus Sci Med; 2020; 7(1):e000396. PubMed ID: 32341791
[TBL] [Abstract][Full Text] [Related]
20. COVID-19 revisiting inflammatory pathways of arthritis.
Schett G; Manger B; Simon D; Caporali R
Nat Rev Rheumatol; 2020 Aug; 16(8):465-470. PubMed ID: 32561873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
